Regeneron (REGN) Reports Dupixent Granted European Commission Approval for Adolescents with Moderate-to-Severe Atopic Sermatitis
Tweet Send to a Friend
Renegeron (NASDAQ: REGN) announced the European Commission (EC) today extended the marketing authorization for Dupixent® (dupilumab) in the European Union ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
